ABOS
NASDAQAcumen Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks62-67%
2025-10-262026-04-19
Mix2190d
- SEC Filings9(43%)
- Other6(29%)
- Insider4(19%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form DEF 14A filed by Acumen Pharmaceuticals Inc.DEF 14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form SCHEDULE 13G filed by Acumen Pharmaceuticals Inc.SCHEDULE 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
- SECSEC Form EFFECT filed by Acumen Pharmaceuticals Inc.EFFECT - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 424B3 filed by Acumen Pharmaceuticals Inc.424B3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form S-3 filed by Acumen Pharmaceuticals Inc.S-3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form S-8 filed by Acumen Pharmaceuticals Inc.S-8 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 10-K filed by Acumen Pharmaceuticals Inc.10-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business HighlightsExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceut
- PRAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Acumen Pharmaceuticals Inc.SCHEDULE 13D/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
- PRAcumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new research findings at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two poster presentations, the data showcase efforts to advance AD treatment through three key areas which include: developing enhanced brain delivery (EBD™) methods for sabirnetug by developing bispecific
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery PortfolioFinancing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen's transferrin-receptor targeting Enhanced Brain Delivery (EBD™) programCandidates exceeded key preclinical criteria, demonstrating elevated brain exposure in non-human primates up to 40-fold over native antibodies, low risk of anemia, and robust stability profiles to enable subcutaneous administrationLead clinical candidate IND targeted for mid-2027 NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinica
- INSIDERSEC Form 4 filed by Acumen Pharmaceuticals Inc.4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- PRAcumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumNEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid
- INSIDERChief Legal Officer & Corp Sec Meisner Derek M exercised 9,406 shares at a strike of $1.85 and sold $28,311 worth of shares (9,406 units at $3.01) (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- PRAcumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new data regarding enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker treatment responses, and the development of new AβO-targeting antibodies. The conference will be held in-person and
- INSIDERChief Legal Officer & Corp Sec Meisner Derek M exercised 17,756 shares at a strike of $1.85 and sold $53,280 worth of shares (17,756 units at $3.00) (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERChief Legal Officer & Corp Sec Meisner Derek M sold $16,721 worth of shares (8,934 units at $1.87), decreasing direct ownership by 5% to 173,999 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERChief Medical Officer Siemers Eric sold $5,833 worth of shares (3,226 units at $1.81), decreasing direct ownership by 1% to 255,371 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERCFO & Chief Business Officer Zuga Matt sold $7,607 worth of shares (4,160 units at $1.83), decreasing direct ownership by 1% to 304,924 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERChief Executive Officer Oconnell Daniel Joseph sold $21,993 worth of shares (12,035 units at $1.83), decreasing direct ownership by 1% to 881,275 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)